The combination of belzutifan (Welireg) and lenvatinib (Lenvima) led to superior outcomes, compared with cabozantinib (Cabometyx), in a phase 3 trial of patients with advanced clear cell renal cell ...
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options ...
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results